Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a research note issued on Friday, March 9th. They currently have a $253.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $256.00. Wedbush’s price target would suggest a potential upside of 321.67% from the company’s current price. Wedbush also issued estimates for Intercept Pharmaceuticals’ FY2021 earnings at $10.38 EPS and FY2022 earnings at $21.42 EPS.
Several other research analysts have also commented on the company. Leerink Swann reiterated a “hold” rating and set a $60.00 price target on shares of Intercept Pharmaceuticals in a report on Tuesday, November 28th. ValuEngine upgraded shares of Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub lowered shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Deutsche Bank assumed coverage on shares of Intercept Pharmaceuticals in a report on Tuesday, December 12th. They issued a “buy” rating and a $106.00 price objective on the stock. Finally, Citigroup set a $74.00 price objective on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, December 21st. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $128.75.
Shares of NASDAQ ICPT traded down $1.52 during midday trading on Friday, reaching $60.00. 873,988 shares of the stock were exchanged, compared to its average volume of 852,038. Intercept Pharmaceuticals has a twelve month low of $51.05 and a twelve month high of $135.59. The stock has a market capitalization of $1,548.62, a price-to-earnings ratio of -4.17 and a beta of -1.81. The company has a debt-to-equity ratio of 21.71, a current ratio of 4.31 and a quick ratio of 4.31.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.04). The company had revenue of $37.69 million during the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. Intercept Pharmaceuticals’s revenue was up 173.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($4.84) EPS. analysts anticipate that Intercept Pharmaceuticals will post -12.6 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio lifted its stake in Intercept Pharmaceuticals by 15.0% in the second quarter. Public Employees Retirement System of Ohio now owns 7,385 shares of the biopharmaceutical company’s stock valued at $894,000 after buying an additional 965 shares during the last quarter. Alps Advisors Inc. lifted its stake in Intercept Pharmaceuticals by 9.5% in the third quarter. Alps Advisors Inc. now owns 24,720 shares of the biopharmaceutical company’s stock valued at $1,435,000 after buying an additional 2,147 shares during the last quarter. Bank of Montreal Can lifted its stake in Intercept Pharmaceuticals by 15.8% in the fourth quarter. Bank of Montreal Can now owns 19,073 shares of the biopharmaceutical company’s stock valued at $1,115,000 after buying an additional 2,603 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in Intercept Pharmaceuticals by 68.6% in the third quarter. Cubist Systematic Strategies LLC now owns 6,717 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 2,734 shares during the last quarter. Finally, Oppenheimer & Co. Inc. lifted its stake in Intercept Pharmaceuticals by 145.1% in the third quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 2,833 shares during the last quarter. Institutional investors own 74.27% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://theenterpriseleader.com/2018/04/02/intercept-pharmaceuticals-icpt-receives-outperform-rating-from-wedbush.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.